Rhythm Pharmaceuticals Inc (RYTM)
67.31
+3.41
(+5.34%)
USD |
NASDAQ |
Nov 08, 16:00
67.33
+0.02
(+0.03%)
After-Hours: 20:00
Rhythm Pharmaceuticals Revenue (TTM): 112.53M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 112.53M |
| June 30, 2024 | 101.78M |
| March 31, 2024 | 91.93M |
| December 31, 2023 | 77.43M |
| September 30, 2023 | 61.98M |
| June 30, 2023 | 43.76M |
| Date | Value |
|---|---|
| March 31, 2023 | 33.61M |
| December 31, 2022 | 23.64M |
| September 30, 2022 | 16.66M |
| June 30, 2022 | 13.41M |
| March 31, 2022 | 4.617M |
| December 31, 2021 | 3.154M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
3.154M
Minimum
Dec 2021
112.53M
Maximum
Sep 2024
48.71M
Average
38.69M
Median
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| TG Therapeutics Inc | 264.79M |
| Regeneron Pharmaceuticals Inc | 13.85B |
| Voyager Therapeutics Inc | 143.77M |
| Mirum Pharmaceuticals Inc | 264.38M |